While there are RNAi products on the marketplace, with Alnylam becoming the first company to get a product approved in 2018, it is difficult to get this class of drug distributed through the brain ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

The ability to trigger RNA interference in mammalian cells provides unprecedented opportunities for probing the functions of genes. Many products and resources are there to help. Laura Bonetta ...

RNA interference (RNAi) therapeutics silence genes, disrupting the production of proteins that contribute to disease. Scientists at Alnylam Pharmaceuticals have developed and are testing multiple RNAi ...

The final word in target validation is to reintroduce an RNAi-resistant version of the target gene product into depleted cells and show recovery of function. This can be challenging for large sets ...

In 2002, on the heels of the discovery that RNA interference existed in human cells, the usually reserved journal Science proclaimed RNAi the "breakthrough of the year." Here was a part of the ...

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...